Pfizer stock is undervalued with strong non-COVID growth, robust Q2 2025 results, and strategic R&D pivots. See more on PFE ...

All of us could use a little more monthly income; it’s not just for retired folks anymore. Considering the state of the economy and the rising household expenses, the idea of receiving a monthly ...

This podcast was recorded on August 20, 2025. Tyler Crowe: The AI market is in a frothy mood again, and there's some big shake ups in retail. This is Motley Fool Money.

Despite the positive outlook, Pfizer still faces substantive execution risks. The looming challenge of losing exclusivity on certain drugs could impact revenue streams significantly. Moreover, while ...

The Trump administration is reportedly preparing to withdraw the COVID-19 vaccines from the U.S. market within the coming ...

Real-time index price for TSX Canadian Dividend Aristocrats Index (TXDV), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Asian shares fell across the board Tuesday, taking their cue from a broad decline on Wall Street that reversed some of the ...

For much of the past two years, U.S. markets have been dominated by a higher-for-longer rate regime. Growth stocks, ...

Pfizer Inc. is under the legal spotlight as Enanta Pharmaceuticals launches a patent infringement suit that might ripple ...

Blackstone Inc. just increased its quarterly dividend to $1.03, signaling confidence after a robust earnings report featuring ...